CYTOSORBENTS CORP (CTSO)

CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe

CytoSorbents to Report First Quarter 2024 Operating and Financial Results

CytoSorbents to Report First Quarter 2024 Operating and Financial Results

CytoSorbents to Report First Quarter 2024 Operating and Financial Results...

STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting

CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023

CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CytoSorbents (NASDAQ:CTSO) just reported results for the fourth quarter of 2023...

CytoSorbents Reports Fourth Quarter and Full Year 2023 Results

CytoSorbents Reports Fourth Quarter and Full Year 2023 Results

CytoSorbents Reports Fourth Quarter and Full Year 2023 Results ...

CytoSorbents to Report Fiscal 2023 Operating and Financial Results

CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference

CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference

CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such...

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

CytoSorb Blood Purification Results in Statistically Significant Reductions in Multiple Organ Failure and Dysfunction

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

CytoSorb Blood Purification Results in Significant Decrease in Organ Failure and Dysfunction in Groundbreaking Heart Transplant Randomized Controlled...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such...

CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such...

Dawson James sees Cytosorbents' Cytosorb as approvable, but raises risk (NASDAQ:CTSO)

Dawson James raises risk rating for approval of Cytosorbents' Cytosorb to 30% after mixed data from failed study of a related product, DrugSorb-ATR. Read more here.

CytoSorbents stock drops as DrugSorb-ATR fails key trial

Cytosorbent (CTSO) stock falls 31% as its blood purification system, DrugSorb-ATR, fails in a pivotal trial for patients undergoing cardiac surgeries. Read more here.

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation ...

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

Company insiders participated in the transaction with $435,000 of investment

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

CytoSorbents Strengthens Balance Sheet with $10.3M Registered Direct Offering. Insiders invest $435,000...

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. ...